当前位置: X-MOL 学术Nat. Rev. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
PERSEPHONE - implications for clinical practice in 2019.
Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2019-07-24 , DOI: 10.1038/s41571-019-0256-7
Noam Pondé 1 , Evandro de Azambuja 2
Affiliation  

Five randomized trials have been conducted to prove that shorter duration of trastuzumab treatment (9 weeks or 6 months) can replace the standard duration (1 year). The results of PERSEPHONE, the most recent trial, suggest that the efficacy of a 6-month treatment is non-inferior to that of 1 year, although not for all patients. We discuss these results in the context of current treatment standards.

中文翻译:

PERSEPHONE-对2019年临床实践的影响。

已经进行了五项随机试验,以证明曲妥珠单抗治疗的持续时间较短(9周或6个月)可以代替标准持续时间(1年)。最近的一项试验PERSEPHONE的结果表明,尽管并非对所有患者而言,6个月治疗的疗效均不低于1年。我们在当前治疗标准的背景下讨论这些结果。
更新日期:2019-11-18
down
wechat
bug